Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit–Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA

DOI: 10.1007/s13311-017-0595-y

Keywords: Multiple sclerosis, Fingolimod, Real-world evidence, Benefit–risk profile, Observational study

Full-Text   Cite this paper   Add to My Lib

Abstract:

The online version of this article (10.1007/s13311-017-0595-y) contains supplementary material, which is available to authorized users

Full-Text